Relapsed APL patient with variant NPM-RARa fusion responded to arsenic trioxide-based therapy and achieved long-term survival

International Journal of Hematology

Volumn 91, Issue 4, 2010, Pages 708-710

  Chen, Yan ^a   Gu, Ling ^a   Zhou, Chenyan ^a   Wu, Xueqiang ^b   Gao, Ju ^a   Li, Qiang ^a   Zhu, Yiping ^a   Jia, Cangsong ^a   Ma, Zhigui ^a  

^a SICHUAN UNIVERSITY   (China)

^b Beijing Aerospace General Hospital   (China)

Author keywords

Acute promyelocytic leukemia; Arsenic trioxid; NPM RAR ; PML RAR ; Relapse

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; RETINOIC ACID;

ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; CHIMERA; CHROMOSOME TRANSLOCATION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; INFORMATION; LONG TERM CARE; LOW DRUG DOSE; PRODUCTIVITY; PROMYELOCYTIC LEUKEMIA; SAFETY; SURVIVAL TIME;

ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; OXIDES; RECURRENCE; REMISSION INDUCTION;

EID: 77954543337     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0553-5     Document Type: Article

References (14)

1. Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukemia and APL variants. Best Pract Res Clin Haematol. 2003;16:387-408.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505-2514
3. Catalano A, Dawson MA, Somana K, Opat S, Schwarer A, Campbell LJ, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 2009;110:4073-4076
4. Sanz MA, Grimwade D, Tallman MS, Lowenburg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-1891
5. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med. 1992;12:170-172
6. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002;70:292-299
7. Mathews V, George B, Lakshimi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632
8. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II, clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360
9. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860
10. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxidebased therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106:3342-3347
11. Koken MHM, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/ RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene. 1999;18:1113-1118
12. Redner RL. Variations on a theme: the alternate translocations in APL. Leukemia. 2002;16:1927-1932
13. Okazuka K, Masuko M, Seki Y, Hama H, Honma N, Furukawa T, et al. Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM-RAR fusion. Int J Hematol. 2007;86:246-249
14. Qiu HR, Li JY, Miao KR, Wang R, Zhang JF, Zhang W. A case of acute promyelocytic leukemia with variant t(5;17) and trisomy 22. Chin J Med Genet. 2008;25:430-433